Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Gains from Investment Securities (2017 - 2025)

Historic Gains from Investment Securities for Denali Therapeutics (DNLI) over the last 9 years, with Q3 2025 value amounting to $1.4 million.

  • Denali Therapeutics' Gains from Investment Securities fell 9433.27% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.5 million, marking a year-over-year decrease of 3139.42%. This contributed to the annual value of $32.3 million for FY2024, which is 107783333.33% up from last year.
  • Latest data reveals that Denali Therapeutics reported Gains from Investment Securities of $1.4 million as of Q3 2025, which was down 9433.27% from $2.4 million recorded in Q2 2025.
  • Denali Therapeutics' Gains from Investment Securities' 5-year high stood at $24.0 million during Q3 2024, with a 5-year trough of -$46000.0 in Q3 2022.
  • Its 5-year average for Gains from Investment Securities is $3.1 million, with a median of $4000.0 in 2023.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first tumbled by 15000.0% in 2022, then surged by 83240000.0% in 2024.
  • Quarter analysis of 5 years shows Denali Therapeutics' Gains from Investment Securities stood at $210000.0 in 2021, then crashed by 105.71% to -$12000.0 in 2022, then surged by 91.67% to -$1000.0 in 2023, then soared by 832400.0% to $8.3 million in 2024, then crashed by 83.65% to $1.4 million in 2025.
  • Its Gains from Investment Securities stands at $1.4 million for Q3 2025, versus $2.4 million for Q2 2025 and $4.4 million for Q1 2025.